An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects

Trial Profile

An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs Fimaporfin (Primary) ; Human papillomavirus E7 protein modulators; Keyhole limpet haemocyanin; Poly ICLC
  • Indications Cholangiocarcinoma; Malignant melanoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors PCI Biotech
  • Most Recent Events

    • 09 Sep 2017 Results presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • 24 Aug 2017 Planned number of patients changed from 80 to 110.
    • 24 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top